Alterity Therapeutics Limited (F:PBN) — Market Cap & Net Worth
Market Cap & Net Worth: Alterity Therapeutics Limited (PBN)
Alterity Therapeutics Limited (F:PBN) has a market capitalization of $53.88 Million (€46.08 Million) as of May 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #21612 globally and #1928 in its home market, demonstrating a -14.29% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alterity Therapeutics Limited's stock price €0.01 by its total outstanding shares 10875416329 (10.88 Billion). Analyse Alterity Therapeutics Limited cash flow conversion to see how efficiently the company converts income to cash.
Alterity Therapeutics Limited Market Cap History: 2015 to 2026
Alterity Therapeutics Limited's market capitalization history from 2015 to 2026. Data shows change from $762.87 Million to $76.29 Million (-20.47% CAGR).
Alterity Therapeutics Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alterity Therapeutics Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
-1221.84x
Alterity Therapeutics Limited's market cap is -1221.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $254.29 Million | $142.66K | -$7.73 Million | 1782.53x | N/A |
| 2017 | $432.29 Million | $132.40K | -$7.54 Million | 3265.15x | N/A |
| 2018 | $139.86 Million | $201.17K | -$8.27 Million | 695.22x | N/A |
| 2019 | $114.43 Million | $108.54K | -$12.34 Million | 1054.29x | N/A |
| 2021 | $127.15 Million | $-7.58K | -$15.31 Million | -16773.75x | N/A |
| 2022 | $6.36 Million | $-5.20K | -$12.85 Million | -1221.84x | N/A |
Competitor Companies of PBN by Market Capitalization
Companies near Alterity Therapeutics Limited in the global market cap rankings as of May 4, 2026.
Key companies related to Alterity Therapeutics Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Alterity Therapeutics Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Alterity Therapeutics Limited's market cap moved from $762.87 Million to $ 76.29 Million, with a yearly change of -20.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €76.29 Million | +50.00% |
| 2025 | €50.86 Million | +14.29% |
| 2024 | €44.50 Million | +75.00% |
| 2023 | €25.43 Million | +300.00% |
| 2022 | €6.36 Million | -95.00% |
| 2021 | €127.15 Million | -39.39% |
| 2020 | €209.79 Million | +83.33% |
| 2019 | €114.43 Million | -18.18% |
| 2018 | €139.86 Million | -67.65% |
| 2017 | €432.29 Million | +70.00% |
| 2016 | €254.29 Million | -66.67% |
| 2015 | €762.87 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Alterity Therapeutics Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $53.88 Million USD |
| MoneyControl | $53.88 Million USD |
| MarketWatch | $53.88 Million USD |
| marketcap.company | $53.88 Million USD |
| Reuters | $53.88 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Alterity Therapeutics Limited
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-… Read more